Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 281

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study

Open access
Jabbour, Elias, Kantarjian, Hagop, Ravandi, Farhad, Thomas, Deborah, Huang, Xuelin, Faderl, Stefan, Pemmaraju, Naveen, Daver, Naval, Garcia-Manero, Guillermo, Sasaki, Koji, Cortes, Jorge, Garris, Rebecca, Yin, C Cameron, Khoury, Joseph D, Jorgensen, Jeffrey, Estrov, Zeev, Bohannan, Zachary, Konopleva, Marina, Kadia, Tapan, Jain, Nitin, DiNardo, Courtney, Wierda, William, Jeanis, Vicky, O'Brien, Susan·2015·The Lancet Oncology

Abstract

Background The combination of chemotherapy with a tyrosine kinase inhibitor (TKI) is effective in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Ponatinib is a more potent BCR-ABL1 inhibitor and selectively suppresses the resistant T315I clones. We examined the efficacy and safety of combining chemotherapy with ponatinib for patients with Ph+ ALL in this ongoing Phase II prospective trial. Methods Adult patients with newly diagnosed Ph+ ALL and good performance and organ status received 8 cycles of hyper-CVAD alternating with high dose methotrexate/cytarabine every 21 days. Ponatinib was given at 45 mg daily for the first 14 days of cycle 1 then continuously for the subsequent cycles. Patients in complete remission (CR) received maintenance with ponatinib 45 mg daily with vincristine/prednisone monthly for 2 years followed by ponatinib indefinitely. The primary endpoint for this study was the improvement of median event-free survival from 24 to 36 months. The trial was registered on clinicaltrials.gov with the identifier NCT01424982. Results Thirty-seven patients with a median age of 51 years were treated. The overall complete cytogenetic response, major molecular response, and complete molecular response rates were 32/32 (100%), 35/37 (95%), and 29/37 (78%), respectively. By multiparameter flow cytometry, 35 patients (95%) had no detectable minimal residual disease after a median of 3 weeks of therapy. Grade ≥ 3 toxicity included infections during induction (20 patients), increased liver functional tests (14 patients), thrombotic events (3 patients), myocardial infarction (3 patients), hypertension (6 patients), skin rash (8 patients), and pancreatitis (6 patients). Two potentially related deaths from myocardial infarction were observed. Nine patients underwent allogeneic stem cell transplantation. With a median follow up of 26 months, 29 patients (78%) remain alive and in CR. The 2-year event-free and overall survival rates are 81% and 80%, respectively. Conclusion The first results of this ongoing trial indicate that the combination of chemotherapy with ponatinib is highly effective in achieving early sustained remissions in patients with newly diagnosed Ph+ ALL. New strategies, including dosing titration of ponatinib and optimized control of vascular risk factors may further improve outcomes. ARIAD Pharmaceuticals Inc. provided free drug and financial support from the ARIAD Investigator Sponsored Trial program.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(15)00207-7

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 281

Metadata

Authors
Jabbour, E., Kantarjian, H., Ravandi, F., Thomas, D., Huang, X., Faderl, S., Pemmaraju, N., Daver, N., Garcia-Manero, G., Sasaki, K., Cortes, J., Garris, R., Yin, C. C., Khoury, J. D., Jorgensen, J., Estrov, Z., Bohannan, Z., Konopleva, M., Kadia, T., Jain, N., DiNardo, C., Wierda, W., Jeanis, V., & O'Brien, S.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2015-11
Volume
16
Issue
15
Pages
1547-1555
ISSN
1470-2045 (ISSN-L)
OpenAlex
W1838408716
Cited by
281
References
30
FWCI
33.64
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. https://app.cochat.ai/papers/10.1016/s1470-2045(15)00207-7
The paper
Jabbour, E., Kantarjian, H., Ravandi, F., Thomas, D., Huang, X., Faderl, S., Pemmaraju, N., Daver, N., Garcia-Manero, G., Sasaki, K., Cortes, J., Garris, R., Yin, C. C., Khoury, J. D., Jorgensen, J., Estrov, Z., Bohannan, Z., Konopleva, M., Kadia, T., . . . O'Brien, S. (2015). Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(15)00207-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.